Changes in adherence and associated factors among patients on newly introduced prostaglandin analog and timolol fixed-combination therapy
Received 22 March 2018
Accepted for publication 26 June 2018
Published 27 August 2018 Volume 2018:12 Pages 1567—1577
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Johnny Chen
Yuka Hasebe,1 Kenji Kashiwagi,1 Toyoaki Tsumura,2 Yasuyuki Suzuki,3 Keiji Yoshikawa,4 Hirotaka Suzumura,5 Toshine Maeda,6 Ryuji Takeda,7 Hitomi Saito,8 Makoto Araie8
1Department of Ophthalmology, University of Yamanashi, Yamanashi, Japan; 2Department of Ophthalmology, Fussa Hospital, Tokyo, Japan; 3Department of Ophthalmology, Tokai University, Kanagawa, Japan; 4Yoshikawa Eye Clinic, Tokyo, Japan; 5Suzumura Eye Clinic, Tokyo, Japan; 6Maeda Eye Clinic, Tokyo, Japan; 7Faculty of Agriculture, Kinki University, Nara, Japan; 8Department of Ophthalmology, Kanto Central Hospital of the Mutual Aid Association of Public School, Tokyo, Japan
Purpose: We investigated patient adherence and factors related to a newly introduced prostaglandin analog and timolol fixed-combination eye drops (PGTFC).
Patients and methods: The Glaucoma Research on Adherence to fixed-Combination Eye drops in Japan (GRACE) study group performed a nationwide prospective questionnaire survey. Participants in this study were patients with glaucoma who were scheduled to receive any type of PGTFC for the first time. The participants answered a questionnaire on the day of PGTFC introduction and again at a return visit 4–6 weeks after PGTFC introduction. The physicians in charge were asked to complete a separate questionnaire on the day of PGTFC introduction. One of two leaflets was randomly delivered to each participant before the description of the PGTFC. One leaflet explained how to correctly instill the eye drops, and the other explained the clinical meaning of intraocular pressure reduction in addition to explaining how to correctly instill the eye drops. Nonadherence was defined as forgetting to instill the eye drops one or more times during the week before the return visit.
Results: In total, 3,597 patients (age, 68.4±12.2 years) met the study protocol requirements. PGTFC introduction significantly reduced the number of antiglaucoma eye drops from 1.93±0.78 to 1.34±0.54 (P<0.0001) and significantly improved adherence (P<0.00001). Factors significantly associated with nonadherence at the return visit included a history of nonadherence as reported by either the patient or their physician before introduction, acceptable instillation times as reported by the patient, and burdensome eye drop instillation as reported by the patient. No significant difference was observed between the two leaflets in terms of their effects on adherence.
Conclusion: PGTFC significantly improved adherence and some of the factors that were significantly associated with adherence.
Registration number: UMIN000013696
Keywords: glaucoma, fixed-combination, adherence questionnaire, Japan
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]